Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:20693248rdf:typepubmed:Citationlld:pubmed
pubmed-article:20693248lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:20693248lifeskim:mentionsumls-concept:C0010674lld:lifeskim
pubmed-article:20693248lifeskim:mentionsumls-concept:C0035203lld:lifeskim
pubmed-article:20693248lifeskim:mentionsumls-concept:C0042491lld:lifeskim
pubmed-article:20693248lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:20693248lifeskim:mentionsumls-concept:C1135662lld:lifeskim
pubmed-article:20693248pubmed:issue4lld:pubmed
pubmed-article:20693248pubmed:dateCreated2011-4-1lld:pubmed
pubmed-article:20693248pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20693248pubmed:abstractTextOutcome measures to assess therapeutic interventions in cystic fibrosis (CF) patients with mild lung disease are lacking. Our aim was to determine if the lung clearance index (LCI) can detect a treatment response to dornase alfa in paediatric CF patients with normal spirometry. CF patients between 6-18 yrs of age with FEV(1 )? 80% pred were eligible. In a crossover design, 17 patients received 4 weeks of dornase alfa and placebo in a randomised sequence separated by a 4-week washout period. The primary end-point was the change in LCI from dornase alfa versus placebo. A mixed model approach incorporating period-dependent baselines was used. The mean ± sd age was 10.32 ± 3.35 yrs. Dornase alfa improved LCI versus placebo (0.90 ± 1.44; p = 0.022). Forced expiratory flow at 25-75% expired volume measured by % pred and z-scores also improved in subjects on dornase alfa (6.1% ± 10.34%; p = 0.03 and 0.28 ± 0.46 z-score; p = 0.03). Dornase alfa significantly improved LCI. Therefore the LCI may be a suitable tool to assess early intervention strategies in this patient population.lld:pubmed
pubmed-article:20693248pubmed:commentsCorrectionshttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20693248pubmed:languageenglld:pubmed
pubmed-article:20693248pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20693248pubmed:citationSubsetIMlld:pubmed
pubmed-article:20693248pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20693248pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20693248pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:20693248pubmed:statusMEDLINElld:pubmed
pubmed-article:20693248pubmed:monthAprlld:pubmed
pubmed-article:20693248pubmed:issn1399-3003lld:pubmed
pubmed-article:20693248pubmed:authorpubmed-author:JensenRRlld:pubmed
pubmed-article:20693248pubmed:authorpubmed-author:AminRRlld:pubmed
pubmed-article:20693248pubmed:authorpubmed-author:GustafssonPPlld:pubmed
pubmed-article:20693248pubmed:authorpubmed-author:LouWWlld:pubmed
pubmed-article:20693248pubmed:authorpubmed-author:SubbaraoPPlld:pubmed
pubmed-article:20693248pubmed:authorpubmed-author:RatjenFFlld:pubmed
pubmed-article:20693248pubmed:authorpubmed-author:JabarAAlld:pubmed
pubmed-article:20693248pubmed:authorpubmed-author:KerriganSSlld:pubmed
pubmed-article:20693248pubmed:authorpubmed-author:BalkovecSSlld:pubmed
pubmed-article:20693248pubmed:issnTypeElectroniclld:pubmed
pubmed-article:20693248pubmed:volume37lld:pubmed
pubmed-article:20693248pubmed:ownerNLMlld:pubmed
pubmed-article:20693248pubmed:authorsCompleteYlld:pubmed
pubmed-article:20693248pubmed:pagination806-12lld:pubmed
pubmed-article:20693248pubmed:meshHeadingpubmed-meshheading:20693248...lld:pubmed
pubmed-article:20693248pubmed:meshHeadingpubmed-meshheading:20693248...lld:pubmed
pubmed-article:20693248pubmed:meshHeadingpubmed-meshheading:20693248...lld:pubmed
pubmed-article:20693248pubmed:meshHeadingpubmed-meshheading:20693248...lld:pubmed
pubmed-article:20693248pubmed:meshHeadingpubmed-meshheading:20693248...lld:pubmed
pubmed-article:20693248pubmed:meshHeadingpubmed-meshheading:20693248...lld:pubmed
pubmed-article:20693248pubmed:meshHeadingpubmed-meshheading:20693248...lld:pubmed
pubmed-article:20693248pubmed:meshHeadingpubmed-meshheading:20693248...lld:pubmed
pubmed-article:20693248pubmed:meshHeadingpubmed-meshheading:20693248...lld:pubmed
pubmed-article:20693248pubmed:meshHeadingpubmed-meshheading:20693248...lld:pubmed
pubmed-article:20693248pubmed:meshHeadingpubmed-meshheading:20693248...lld:pubmed
pubmed-article:20693248pubmed:meshHeadingpubmed-meshheading:20693248...lld:pubmed
pubmed-article:20693248pubmed:meshHeadingpubmed-meshheading:20693248...lld:pubmed
pubmed-article:20693248pubmed:meshHeadingpubmed-meshheading:20693248...lld:pubmed
pubmed-article:20693248pubmed:meshHeadingpubmed-meshheading:20693248...lld:pubmed
pubmed-article:20693248pubmed:meshHeadingpubmed-meshheading:20693248...lld:pubmed
pubmed-article:20693248pubmed:year2011lld:pubmed
pubmed-article:20693248pubmed:articleTitleThe effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis.lld:pubmed
pubmed-article:20693248pubmed:affiliationDivision of Respiratory Medicine, Dept of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada. reshma.amin@sickkids.calld:pubmed
pubmed-article:20693248pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:20693248pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:20693248pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:20693248pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:20693248lld:pubmed